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Abstract
The prevalence and impact of type 2 diabetes are reaching epidemic proportions in the United
States. Data suggest that effective management can reduce the risk for both microvascular and
macrovascular complications of diabetes. In treating patients with diabetes, physicians must be
prepared not only to tailor the initial treatment to the individual and his or her disease severity but
also to advance treatment as necessary and in step with disease progression.
The majority of patients with diabetes are not at goal for glycated hemoglobin A1C, fasting plasma
glucose, or postprandial plasma glucose levels. Although lifestyle changes based on improved diet
and exercise practices are basic elements of therapy at every stage, pharmacologic therapy is
usually necessary to achieve and maintain glycemic control. Oral antidiabetic agents may be
effective early in the disease but, eventually, they are unable to compensate as the disease
progresses. For patients unable to achieve glycemic control on 2 oral agents, current guidelines
strongly urge clinicians to consider the initiation of insulin as opposed to adding a third oral agent.
Recent research suggests that earlier initiation of insulin is more physiologic and may be more
effective in preventing complications of diabetes. Newer, longer-lasting insulin analogs and the use
of simplified treatment plans may overcome psychological resistance to insulin on the part of
physicians and patients.
This article summarizes the risks associated with uncontrolled fasting and postprandial
hyperglycemia, briefly reviews the various treatment options currently available for type 2 diabetes,
presents case vignettes to illustrate crossroads encountered when advancing treatment, and offers
guidance to the osteopathic physician on the selection of appropriate treatments for the
management of type 2 diabetes.
Background
The prevalence of type 2 diabetes is reaching epidemic
proportions in the United States. Impacting an estimated
20.8 million people – 7% of the overall US population,
including an astounding 21% of those older than 60 years
[1] – this progressive disease can lead to macrovascular
and microvascular complications [2]. Macrovascular com-
plications (cardiovascular disease and stroke) account for
approximately 65% of all mortality in people with diabe-
tes. Diabetes also is the leading cause of kidney failure and
new cases of blindness among adults aged 20–74 years
[2]. Other microvascular complications of diabetes
include periodontal disease resulting in tooth loss, neu-
ropathy leading to limb amputation, and numerous other
potentially life-threatening complications [2].
Type 2 diabetes has a significant effect on quality of life.
Patients are often concerned about disease progression or
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complications, social stigma, convenience/impact on life-
style, and cost. Many have misperceptions regarding the
complexity of treatment regimens [3,4]. These psychoso-
cial issues also can impede glycemic control. Treatment
must be tailored to the severity of disease. The start of
insulin therapy is often delayed unnecessarily because
both patients and practioners may underestimate the
importance of glycemic control. [5].
The array of treatment options can be complex and chal-
lenging. Several newer therapeutic options have become
available within the past decade. Physicians designing a
treatment strategy are faced with several decisions:
 Choice of the best therapeutic option with each step of
advancing disease;
 When to advance therapy;
 When to initiate insulin; and
 The utility and place of newer agents in a treatment strat-
egy.
Because primary care physicians provide diabetes care for
the great majority of patients with type 2 diabetes (82%),
it is important for this group of physicians to understand
the risks associated with poor glycemic control and the
strategies that will help more patients reach their glycemic
targets [6]. The purpose of this article is to offer guidance
to the osteopath on the selection of appropriate treat-
ments for the management of type 2 diabetes.
Overview: Disease pathology and treatment goals
Type 2 diabetes is a progressive disease characterized by
defects in insulin secretion and utilization [7]. In the nor-
mal postabsorptive state, glucose utilization in insulin-
dependent tissue (primarily muscle) is balanced by glu-
cose production [7]. In type 2 diabetes, tissues become
insulin resistant, the ability of the pancreatic β cells to
secrete insulin is impaired [7], and β-cell function
declines progressively over time (Figure 1) [8].
The American Diabetes Association (ADA) and the Amer-
ican Association of Clinical Endocrinologists (AACE)
have issued recommendations for target levels of glycemic
control (Table 1) [9,10]. The ADA recommends that gly-
cated hemoglobin A1C (hereafter A1C) be measured rou-
tinely in all patients with diabetes, initially to assess
glycemic control and then as part of continuing care [9].
While A1C reflects the average level of glycemic control
over a 3-month period of time, day-to-day control is dem-
onstrated by both basal and postprandial plasma glucose
(PPG) levels. Effective treatment, therefore, should
encompass the means to control both basal and PPG
excursions.
The role of postprandial versus basal hyperglycemia has
been examined to ascertain the relative contribution of
each to overall metabolic disequilibrium in type 2 diabe-
tes [11]. In patients with mild to moderate hyperglycemia
(A1C  ≤ 8.4%), postprandial hyperglycemia has been
shown to be an important contributor to the overall level
of hyperglycemia [11]. Basal hyperglycemia becomes a
major contributor in patients with poorly controlled and
more extensive hyperglycemia (A1C ≥ 8.5%) [11]. How-
ever, these cutoff points are fluid; the respective contribu-
tion of each type of hyperglycemia shifts with the level of
overall glycemic control as reflected by the A1C measure.
The role of PPG elevations decreases as the patient's glyc-
emic control deteriorates [11].
Improved glycemic control reduces the risk of microvascu-
lar complications and macrovascular events in type 2 dia-
betes [12,13]. Tight control in patients with type 1
diabetes also reduces the risk of macrovascular events and
Table 1: ADA and AACE Glycemic Goals
ADA AACE
A1C < 7.0%* < 6.5%
FPG 90–130 mg/dL < 110 mg/dL
PPG < 180 mg/dL < 140 mg/dL
A1C = glycated hemoglobin A1C; AACE = American Association of 
Clinical Endocrinologists; ADA = American Diabetes Association; 
FPG = fasting plasma glucose; PPG = postprandial plasma glucose.
*Physicians and patients should attempt to achieve a level as close to 
normoglycemia (< 6.0%) as possible without experiencing serious 
adverse events.
Progressive loss of β-cell function in type 2 diabetes Figure 1
Progressive loss of β-cell function in type 2 diabetes. 
At diagnosis, a patient with type 2 diabetes has half the β cells 
as a person without type 2 diabetes. U.K. Prospective Diabe-
tes Study Group. Diabetes. 1995;44:1249–1258 [8].
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cardiovascular disease [14,15]. However, most patients
with diabetes are not at goal for glycemic control or cardi-
ovascular risk factors. According to recent data from the
National Health and Nutrition Examination Survey, <
50% of patients with self-reported diabetes were at target
A1C; 36% met target low-density lipoprotein (LDL) cho-
lesterol goals for low-risk status; < 28% were at the low-
risk status because of their high-density lipoprotein cho-
lesterol levels; and < 40% met target blood pressure goals
[16]. Long-standing failure to achieve glycemic control
has been associated with increased risk for cardiovascular
events [17]. The Heart Outcomes Prevention Evaluation
study reported a progressive association between glycemia
indices and incident cardiovascular events, nephropathy,
and total mortality [17]. Therefore, an improvement in
the achievement of these goals may greatly improve the
health outcomes of patients with diabetes [9].
Progressive therapeutic management of type 2 diabetes
Lifestyle modification is an important component of care
throughout all stages of diabetes, and should be initiated
and maintained as the basis of therapy (Figure 2) [18,19].
Lifestyle changes include medical nutrition therapy, phys-
ical fitness programs with 30 minutes of exercise 5 times
per week, and weight loss (if the patient is overweight;
5%–7% reduction in body weight) [18]. These strategies
have been shown effective in delaying the onset of type 2
diabetes in clinical studies [9,18] and decreasing A1C by
1.0% to 2.0% [19]. It is important to note that lifestyle
modification is never abandoned in favor of medical ther-
apy. Rather, it constitutes the backbone of diabetes ther-
apy throughout disease progression [18,19]. Such lifestyle
changes may increase the probability that other therapies
will be effective [20].
As most patients will not achieve glycemic goals with diet
and exercise alone, the ADA and the European Society for
the Study of Diabetes suggest lifestyle intervention plus
metformin as a first step in therapy [9]. Metformin is the
preferred oral antidiabetic drug (OAD) if the patient is
overweight, since it promotes weight loss and does not
cause hypoglycemia [20]. If glycemic goals are not met
with one OAD, a second is added; commonly, a sulfony-
lurea is added to metformin therapy [20]. As the disease
progresses, treatment with additional medications
becomes necessary to meet glycemic goals: a third agent
from a different class, such as a thiazolidinedione, could
be added or a basal insulin could be initiated [20]. A con-
Progression of therapy in type 2 diabetes Figure 2
Progression of therapy in type 2 diabetes. ADA recommended algorithm. Nathan DM et al. Diabetes Care. 
2006;29:1963–1972 [19].
Diagnosis of T2DM
Lifestyle Intervention + Metformin
If not at goal
Add 2nd oral agent or basal insulin (titrate to goal)
Add 3rd oral agent or basal insulin; or intensify insulin*
*Intensify insulin = continue titrating basal insulin to goal or add prandial insulin to meals, beginning 
with the largest meal of the day.
If not at goal
Maximum of 
2-3 monthsOsteopathic Medicine and Primary Care 2008, 2:4 http://www.om-pc.com/content/2/1/4
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sensus statement from the ADA provides a comprehensive
review of the benefits and disadvantages of OADs [19].
The decision of when to initiate insulin therapy can be
challenging. Patients and physicians may resist this step in
the mistaken belief that regimens are too complex and in
the fear that hypoglycemia is difficult to avoid. However,
most patients with type 2 diabetes will eventually require
treatment with insulin due to the progressive decline of β-
cell function (Figure 1), insulin resistance, and glucotox-
icity that occur with the disease [7]. Many patient miscon-
ceptions and fears about insulin can be overcome with
appropriate education and open communication. Fur-
thermore, the use of newer, simple patient-driven algo-
rithms permits patients to titrate insulin to goal with a
reduced risk of hypoglycemia [21,22].
Currently available products offer opportunities for more
individualized treatment and simpler regimens, and it is
becoming increasingly clear that earlier insulin therapy
can provide clinical benefit [23]. For example, systemati-
cally titrating bedtime basal insulin that had been added
to oral therapy was shown to safely achieve an A1C of
7.0% in a majority of patients with type 2 diabetes whose
A1C had been 7.5% to 10.0% while they were receiving
oral agents alone [23].
Patients and clinicians are advised to avoid complacency
and must aggressively move up the treatment ladder when
glycemic targets are not met. Clinicians' failure to inten-
sify therapy when indicated – so-called clinical inertia –
may prevent patients from meeting their glycemic goals
[24]. In one retrospective analysis, a quality improvement
intervention aimed at overcoming clinical inertia in a dia-
betes clinic setting led to more frequent intensification of
therapy and lower A1C levels [24,25].
Insulin: Benefits of early initiation
The long-standing assumption that insulin should be
used as a last-resort intervention during treatment of
patients with type 2 diabetes is now being challenged.
Until recently, it was believed that insulin should be initi-
ated only when combined lifestyle approaches and 1 or
more OADs failed to achieve glycemic goals [26]. In addi-
tion to patients' fear of injections and concerns about life-
style disruption, many physicians believed that insulin
increased the risk of cardiovascular disease. On the con-
trary, studies have demonstrated that insulin has several
potentially beneficial cardiovascular properties [26].
Among these is a marked reduction in inflammatory indi-
ces [27]. These benefits may not extrapolate to non-insu-
lin antidiabetes agents, as recent data indicate a potential
risk for cardiovascular morbidity and mortality in patients
taking an oral thiazolidinedione agent [28], although
these data must be interpreted with caution [29].
Data show that glucose is proinflammatory and that
hyperglycemia is potentially toxic [30]. Insulin is an effec-
tive anti-inflammatory measure, since it normalizes
plasma glucose and exerts significant anti-inflammatory
effects [27]. Thus, the decision to delay insulin and
instead add a third OAD may prolong the state of toxic
hyperglycemia.
While the addition of basal insulin when OAD fails is now
an established practice, whether to add insulin earlier or
later in disease progression has remained controversial
[31]. The United Kingdom Prospective Diabetes Study
demonstrated the advantages of the early addition of insu-
lin to conventional diet-plus-OAD treatment if the fasting
plasma glucose (FPG) remained > 108 mg/dL despite
maximal doses of sulfonylurea [31]. Over 6 years, ~ 53%
of patients receiving sulfonylureas met the study require-
ment for additional insulin therapy [31]. Compared with
the insulin-alone treatment group, significantly more
patients in the added-insulin group had A1C < 7.0% over
the 6-year study period, and their median A1C was signif-
icantly lower (6.6%) than that of the group taking insulin
alone (7.1%) [31].
Basal and prandial insulin
Table 2 lists currently available insulin formulations.
Since the beginning of insulin therapy more than 75 years
ago, a variety of improvements have resulted in the avail-
ability of numerous human insulin formulations with dif-
ferent onsets of action, peak concentrations, and
durations of effect [32]. Judicious selection of specific
insulin formulations to supplement OAD agents is an
effective tactic to help patients reach glycemic goals [32]
(Figure 3).
Effective treatment should target both basal and PPG lev-
els. Fasting and postprandial glycemia both are abnormal
in type 2 diabetes, and the basal-bolus insulin strategy
most closely resembles normal physiologic patterns [32].
As a starting point, a single injection of basal insulin can
be used to provide 24-hour control of glycemia in patients
in whom oral agents no longer constitute adequate ther-
apy [32].
Basal insulin
Newer long-acting insulin formulations represent an
improvement over neutral protamine Hagedorn (NPH)
insulin, the basal insulin that has been used for many
years. Recombinant DNA technology has produced insu-
lin analogs – insulin glargine and insulin detemir – with
structural modifications that improve their time-action
profiles such that they more closely resemble physiologic
insulin patterns [33].Osteopathic Medicine and Primary Care 2008, 2:4 http://www.om-pc.com/content/2/1/4
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Trials evaluating insulin glargine versus NPH insulin
added to existing OAD therapy have found that treatment
with either agent resulted in similar improvements in gly-
cemic control [23,34,35]. However, insulin glargine was
associated with less nocturnal hypoglycemia than NPH
insulin [23,34,35]. This is likely due to the 24-hour dura-
tion of action with no pronounced peak activity of insulin
glargine. Yki-Jarvinen et al performed a meta-regression
analysis of clinical trials that used either NPH or insulin
glargine as treatment options and observed that at equiv-
alent rates of hypoglycemia, insulin glargine was associ-
ated with significantly lower A1C levels than NPH insulin
[36].
Insulin detemir is approved for once- or twice-daily dos-
ing and exhibits an activity peak at approximately 6–8
hours following administration [37]. Clinical trials com-
paring insulin detemir and NPH insulin have indicated
that treatment with insulin detemir results in comparable
improvements in A1C, less weight gain, and reduced risk
for hypoglycemia [38].
Clinical case: A patient recently diagnosed with type 2 
diabetes
Case History
Mr. Madera is a 45-year-old Hispanic man recently diag-
nosed with type 2 diabetes. He is 5 ft 9 in tall and weighs
225 lb; his body mass index (BMI) is 33 kg/m2. He
smokes 1 pack of cigarettes per day. During a recent visit
to the clinic, his FPG level was 235 mg/dL and his A1C
level was 10.6%. His blood pressure, total cholesterol,
LDL cholesterol, and triglycerides were elevated. Mr. Mad-
era's physician created a treatment plan that included
patient education, diet, exercise, and smoking cessation.
Additionally, oral therapy with metformin was initiated,
along with aggressive management of the patient's cardio-
vascular risk factors.
At the 3-month follow-up, his A1C decreased to 9.2%. At
that time, he was receiving 1000 mg of metformin per day.
Idealized profiles of human insulin and analogs Figure 3
Idealized profiles of human insulin and analogs.
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Table 2: Currently Available Insulin Formulations
Insulin Formulation Coverage Duration of 
Action
Dosing Special Considerations
NPH insulin [69] Basal 13 hours Twice daily Nocturnal hypoglycemia; morning 
hyperglycemia; intersubject variability
Insulin glargine [69,70] Basal 24 hours Once daily Less risk of hypoglycemia (overall and 
nocturnal) compared with NPH insulin; once-
daily dosing
Insulin detemir [38,45,71] Basal 14 hours Once or twice daily Less nocturnal hypoglycemia and less weight 
gain compared with NPH insulin; most patients 
require twice-daily dosing
RHI [40] Prandial 6–8 hours 30 minutes premeal Limited mealtime flexibility
Insulin lispro [42,72] Prandial 3–4 hours Up to 15 minutes premeal or 
immediately postmeal
Pregnancy category B rating
Insulin aspart [40,44] Prandial 3–4 hours Up to 15 minutes premeal or 
immediately postmeal
Pregnancy category B rating.
Insulin glulisine [72,73] Prandial 3–4 hours Up to 15 minutes premeal or up 
to 20 minutes after start of meal
Only rapid-acting agent evaluated in 
conjunction with a dosing algorithm
Premix (human)
70% NPH, 30% RHI
50% NPH, 50% RHI
Basal-prandial 16–24 hours Prebreakfast and presupper Short- and long-acting components in fixed 
ratio; difficult to titrate, increased risk of 
hypoglycemia
Premix (insulin analogs)
75% NPL, 25% lispro
50% NPL, 50% lispro
70% protamine aspart, 30% 
aspart
Basal-prandial 16–24 hours Prebreakfast and presupper Short- and long-acting components in fixed 
ratio; difficult to titrate, increased risk of 
hypoglycemia
NPH = neutral protamine Hagedorn; NPL = neutral protamine lispro; RHI = regular human insulin.Osteopathic Medicine and Primary Care 2008, 2:4 http://www.om-pc.com/content/2/1/4
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As the consensus algorithm from the ADA and the Euro-
pean Association for the Study of Diabetes recommends
rapid intensification of therapy if patients fail to meet
their glycemic goal with lifestyle changes in addition to
treatment with metformin and if A1C levels remain >
8.5% [19], Mr. Madera's physician was concerned about
his hyperglycemia and recommended the initiation of
basal insulin therapy rather than the addition of a second
OAD. However, Mr. Madera was concerned about injec-
tions and indicated that he preferred to delay the addition
of insulin and wanted to try combination OAD therapy.
Therefore, glimepiride was added to his current oral regi-
men at 4 mg once daily.
At his 6-month follow-up, Mr. Madera's A1C was 8.0%,
and he had gained 4 lb. The physician discussed possible
treatment options with Mr. Madera. His physician sug-
gested initiating insulin therapy and demonstrated how to
administer injections. Mr. Madera practiced the injection
technique and decided to try treatment with insulin. Insu-
lin glargine was added to Mr. Madera's existing regimen of
metformin (1000 mg/d) and glimepiride (4 mg/d). Mr.
Madera was instructed to begin with 10 units of insulin
glargine administered at bedtime and adjust his dose
weekly until he reaches a target FPG ≤ 100 mg/dL
Three months later, Mr. Madera was on 1000 mg/d of
metformin, 4 mg/d of glimepiride, and 40U of insulin
glargine administered once in the evening. His A1C had
decreased to 7.2%, his FPG was 110 mg/dL, and he had no
confirmed episodes of hypoglycemia. Mr. Madera
reported that the insulin injections were not painful, and
he will continue to titrate his dose of insulin glargine until
his blood glucose reaches target. His weight had increased
slightly, so the importance of continuing lifestyle modifi-
cation was reinforced and a dietician was recommended.
Case discussion
This case highlights the need for aggressive management
to achieve glycemic goals. Diet, exercise, and therapy with
oral agents are all beneficial in patients with type 2 diabe-
tes, but these interventions alone were unable to bring Mr.
Madera's blood glucose levels to goal. At this point, some
might consider adding a third oral agent. Nevertheless,
clinical research has shown this approach to be less effec-
tive in glycemic control and less cost-effective compared
with the initiation of insulin [39]. The addition of a basal
insulin was able to bring Mr. Madera's blood glucose lev-
els close to goal within 12 weeks, and with continued
titration of his basal insulin component Mr. Madera
should soon meet target glucose levels. It is important to
stress that lifestyle modification must be continued
throughout treatment.
Prandial insulin
When A1C levels are not at target, prandial insulin can be
added gradually to basal insulin therapy to provide post-
prandial control of glycemia. Prior to the development of
short-acting insulin analogs, prandial control with regular
human insulin (RHI) often was challenging due to varia-
bility in absorption and time to reach peak levels, as well
as to frequent hypoglycemia resulting from the use of
higher insulin doses to compensate for postprandial
hyperglycemia [40].
Compared with RHI, the 3 rapid-acting insulin analogs
(insulin aspart, insulin lispro, and insulin glulisine) have
absorption and action profiles that more closely resemble
physiologic insulin secretion in response to a meal [41].
Insulin lispro has a more rapid onset, an earlier peak, and
a shorter duration of glucose-lowering activity than RHI
[42]. Ross et al reported better adherence with insulin lis-
pro than with RHI in a study of patients with type 2 dia-
betes [43]. Lispro improved 2-hour PPG levels, quality of
life, and overnight hypoglycemia rates, with A1C levels
equivalent to those achieved with RHI. [43]. Insulin lispro
is approved for use 15 minutes before or immediately
after a meal [42].
Insulin aspart has a more rapid onset of action than RHI.
However, the rate of insulin absorption and therefore the
onset of aspart activity may vary by injection site, exercise,
and other variables [44]. Aspart used with insulin detemir
in basal-bolus therapy resulted in more predictable FPG
levels and significantly lower within-person variation
compared with a regimen of NPH plus RHI. Further, the
risk of nocturnal hypoglycemia was 38% lower with the
aspart plus detemir regimen [45].
Insulin glulisine added to insulin glargine produced effec-
tive basal-prandial glycemic control, even in obese
patients. Interestingly, Jungmann et al have reported that
postprandial insulin glulisine produced a slightly lower
blood glucose profile than preprandial glulisine in obese
patients who were also receiving basal insulin [46]. This
may be advantageous for younger patients with type 2 dia-
betes, who often prefer postprandial injections. Bergenstal
and colleagues demonstrated that the use of a novel meal-
time dosing algorithm with insulin glulisine was a safe
and effective alternative to carbohydrate counting [47]. In
this study, patients used the algorithm to adjust doses of
insulin glulisine by 1, 2, or 3 U based on premeal glucose
patterns, with glargine as the bolus insulin [47]. Although
this algorithm was specific to insulin glulisine, it may also
apply to other rapid-acting insulin analogs; however, to
date, there have been no studies assessing the use of this
algorithm with other rapid insulins.Osteopathic Medicine and Primary Care 2008, 2:4 http://www.om-pc.com/content/2/1/4
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Although all 3 of these prandial insulin analogs have a
rapid onset of action, slight differences exist in the
approved timing of injections. Insulin lispro [42] is
approved for use 15 minutes before or immediately after
a meal; glulisine [48] for 15 minutes before or within 20
minutes after starting a meal; and insulin aspart is
approved for administration immediately before a meal
(start of meal within 5–10 minutes after injection) [44].
Irrespective of the specific insulin chosen, the insulin reg-
imen should be customized to individual needs. Some
patients may require 1 injection daily, while others may
require 2–4. All of these prandial insulin analogs are avail-
able in disposable pen devices for easy administration.
Premixed insulin
While offering the convenience of 2 injections per day,
premixed insulin poses a challenge with respect to dose
titration, since the ratio of short-acting to long-acting
components is fixed. Oikine et al have reported that twice-
daily administration of premixed insulin resulted in
improved glycemic control after morning and evening
meals, but a change in overall A1C values was not
observed [49]. In patients not reaching goal with twice-
daily injections with premixed insulin, the addition of a
prandial insulin injection at lunchtime can become neces-
sary. In such cases, the morning insulin dose should be
decreased accordingly [6]. Because it is important that
patients adhere to a strict meal schedule to minimize the
risk of hypoglycemia, treatment with a premixed insulin
regimen can limit patient flexibility with respect to meal-
times.
Clinical case: Recurrent hypoglycemia
Case history
Mrs. Martin, a 57-year-old woman, was diagnosed with
type 2 diabetes 5 years prior and recently was referred for
diabetes management. Her self-monitored blood glucose
levels ranged from 250–350 mg/dL. She has a regular exer-
cise routine – walking 4–5 days a week – and maintains a
reasonable diet. This patient is 5 ft 7 in tall and weighs 170
lb, with a BMI of 26.6 kg/m2. She described burning pains
in both feet at night. Her medications include glyburide
10 mg twice daily and metformin 500 mg twice daily;
higher doses of metformin had caused diarrhea. Pioglita-
zone had been prescribed in the past, but its use was dis-
continued due to pedal edema. Her A1C level is 9.3%.
Mrs. Martin began treatment with basal insulin, and the
dose was titrated to her FPG goal. However, her PPG
remained elevated (high 200s). Her physician suggested
supplementing with prandial insulin, but the patient was
unwilling to take 4 injections per day. Basal insulin was
discontinued and the physician was prescribed a
premixed insulin regimen (eg, 70% basal insulin aspart
protamine and 30% prandial insulin aspart with breakfast
and dinner); the dose was titrated to 40 U twice daily.
Within a few weeks, Mrs. Martin returned to report erratic
blood glucose levels (either in the high 200s or in the low
50s) and recurrent symptoms of hypoglycemia (shaki-
ness, anxiety, sweating) in conjunction with low blood
glucose measures. She was transitioned back to her previ-
ous basal insulin regimen, and a bolus regimen of insulin
glulisine was initiated. Titration was completed in a sim-
ple stepwise fashion, starting with the largest meal and
adding injections prior to each meal until target glycemic
control (A1C < 7.0%, PPG < 140 mg/dL) was achieved.
This regimen may afford the patient greater flexibility with
fewer hypoglycemic episodes [47].
Case discussion
Hypoglycemia can be a bothersome, though rarely seri-
ous, adverse event in patients with type 2 diabetes who are
treated with insulin therapy. This case illustrates how
insulin therapy can be optimized to improve glycemic
control and to avoid hypoglycemia. Patients often con-
sider the initiation of insulin therapy a major barrier to
overcome because of a misconception that regimens are
complex. In this case, postprandial blood glucose was
above the target range, thus requiring a prandial insulin to
optimize glycemic control. Adding a fast-acting insulin
analog to the basal insulin would have been effective, but
the patient initially did not want to take 4 injections, so an
analog mix was prescribed. This patient's blood glucose
control then became erratic, and she experienced a
number of hypoglycemic episodes. Although not all
patients have the same experience, for this patient, multi-
ple daily injections provided a physiologic approach to
glycemic control and allowed the patient greater flexibility
as the medication could be tailored to address her fluctu-
ations.
Newer agents
Among the most recent introductions to the market for
antidiabetes agents are a new, inhaled prandial insulin
[50] and several mimetic agents based on gastrointestinal
peptide hormones that, in concert with insulin and gluca-
gon, regulate fuel homeostasis and eating behavior [51].
Research to date shows promise for the noninsulin agents
as adjuncts to basal and prandial insulin therapy, but their
place in the diabetes treatment algorithm has yet to be
determined.
Inhaled insulin
In January 2006 the US Food and Drug Administration
(FDA) approved an inhaled powder form of recombinant
human insulin for the prandial treatment of adult patients
with type 1 and type 2 diabetes [52]. It is absorbed as
quickly as subcutaneously administered rapid-acting insu-Osteopathic Medicine and Primary Care 2008, 2:4 http://www.om-pc.com/content/2/1/4
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lin analogs and more quickly than subcutaneous RHI,
with absorption independent of BMI [50]. Inhaled insulin
provides postprandial glycemic control when added to
long-acting basal insulin, with a duration of action com-
parable to that of RHI [53]. Pulmonary function assess-
ment is required prior to initiating therapy [50]. Although
a non-injectable route of administration may appeal to
some patients, the inhaler unit may be cumbersome. In
fact, as of October 18, 2007, Pfizer Inc. halted production
of its inhaled insulin powder due to lack of uptake of the
product; however, there are other devices in development.
There are currently no head-to-head data comparing
inhaled insulin with rapid-acting insulin analogs.
Incretin mimetics
The first such agent in its class, exenatide is an incretin
mimetic that mimics the glucagonlike peptide 1, a natural
hormone secreted in response to the ingestion of food
[54]. Approved by the FDA in 2005 as an adjunct therapy
for type 2 diabetes, exenatide given as twice-daily injec-
tions enhances insulin release in response to elevated
blood glucose levels, inhibits glucagon secretion after
meals, slows the rate of gastric emptying (which reduces
nutrient absorption into the bloodstream), and increases
satiety thereby promoting reduced food intake [54]. In
clinical studies, exenatide improved glycemic control and,
over time, A1C in patients whose type 2 diabetes had been
worsening with maximal doses of a sulfonylurea, with
metformin, and with combined sulfonylurea and met-
formin treatment [55-57]. Overall, A1C levels declined
significantly over the course of the studies, plateauing
after 12 weeks of therapy [55-57]. In the patients with type
2 diabetes who did not reach normoglycemia on a combi-
nation therapy of sulfonylurea and metformin, adjunctive
exenatide or insulin glargine each reduced A1C by 1.1%,
with about 46% of patients on each therapy achieving
A1C ≤ 7.0% [58]. Insulin glargine, however, reduced FPG
to a greater extent, and a greater percentage of patients
achieved FPG < 100 mg/dL [58]. More patients withdrew
from exenatide treatment due to nausea or other gastroin-
testinal symptoms (18 vs 1 in the insulin glargine group)
[58]. Nausea affected approximately half of patients on
exenatide in the studies, especially at high doses [55-57].
Minimal dose titration, mild hypoglycemia, and weight
loss may be advantages of exenatide [59]. The FDA
recently reviewed 30 postmarketing reports of acute pan-
creatitis in patients taking exenatide and requested that
information about acute pancreatitis be added to the
product label. Patients should be instructed to seek
prompt medical care if they experience unexplained per-
sistent severe abdominal pain which may or may not be
accompanied by vomiting [60]. Other limiting factors of
exenatide may be cost, gastrointestinal side effects, and
potential interaction with oral contraceptives and antibi-
otics [59,61].
Pramlintide
An analog of amylin, a pancreatic peptide secreted by β
cells in response to meals, pramlintide used in insulin-
treated patients with type 1 diabetes and type 2 diabetes
reduces PPG excursions, lowers A1C levels another 0.4%
to 0.6%, increases satiety, and decreases food intake [62].
Its mechanism of action is independent of and additive to
insulin. Approved in 2005, pramlintide is initiated at 15
μg subcutaneously with each meal and is titrated up to 30
or 60 μg per meal, depending on the dose-limiting side
effect of nausea. Then the insulin dose is decreased by
50% or to the degree that maintains glycemic control
without causing hypoglycemia [62]. Weight loss has been
noted in obese and overweight patients [62].
Sitagliptin
Approved in 2006, sitagliptin inhibits dipeptidyl pepti-
dase 4 (DPP-4), an inactivator of gut incretin hormones,
which reduce postprandial and fasting glucose concentra-
tions. By blocking this inactivation, the DPP-4 inhibitor
increases active incretin levels and effects [63]. Sitagliptin
100 mg, given orally once per day, is approved for mono-
therapy or adjunctive therapy with metformin or a thiazo-
lidinedione, or with the combination of sulfonylurea and
metformin in patients with type 2 diabetes who have
experienced inadequate glycemic response on OADs [64].
Clinical studies have shown improvements in A1C, FPG,
and PPG with no increased risk of hypoglycemia and a
slight increase in abdominal discomfort compared with
placebo [63,65,66]. In March 2007, the FDA approved a
combination product containing sitagliptin and met-
formin [67].
Conclusion
Type 2 diabetes is a highly prevalent, progressive disease,
characterized by defects in insulin production and utiliza-
tion and is associated with significant morbidity and mor-
tality.
The glucose levels of most type 2 diabetic patients are not
well controlled. Therefore, treatment regimens should be
individualized and optimized to achieve glycemic targets
in addition to managing other risk factors.
Diet, exercise and oral agents are effective for reducing
A1C; however, they do not sufficiently compensate for
progressively worsening β-cell function and insulin resist-
ance. Physiologic insulin replacement in the form of
basal-bolus insulin manages background and postpran-
dial glycemic excursions well. In addition, newer treat-
ment options hold promise but require additional clinical
study and evaluation to determine their appropriate place
in a treatment paradigm.Osteopathic Medicine and Primary Care 2008, 2:4 http://www.om-pc.com/content/2/1/4
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